Biocomposites launches two new phase II trials

Biocomposites launches two new phase II trials of Stimulan VG mixed with vancomycin and gentamicin in US

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, announces the launch of two phase II clinical trials of Stimulan VG in the US.

Both trials are part of an investigational new drug (IND) application that will evaluate the safety and efficacy of Stimulan VG (Stimulan mixed with vancomycin and gentamicin).

Biocomposites is now recruiting patients to its BLADE-VG2 trial, which will evaluate the safety and efficacy of Stimulan VG in treating diabetic foot osteomyelitis. In addition, Biocomposites will shortly be commencing its BLADE-OPU2 trial, which will investigate the safety and efficacy of Stimulan VG in treating stage IV pressure ulcers.

With over 500K diabetic foot osteomyelitis and 200K stage IV pressure ulcer cases in the US every year, the need to transform patient outcomes in these areas and minimise the use of systemic antibiotics has never been more important.

Michael Harris, chief executive officer said: “The Stimulan VG trials are an important next step in our mission to be the ‘go to’ provider for surgeons seeking products to help them in their infection management cases. Diabetic foot osteomyelitis and stage IV pressure ulcers can severely impact a patient’s quality of life and are a burden to healthcare systems. These trials aim to demonstrate the potential for Stimulan VG to transform patient outcomes, minimise use of antibiotics and save healthcare systems significant sums of money by reducing the incidence of recurrent infection.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!